Key Highlights

  • The 18 August result therefore landed near the top of a much lower bar.
  • Cochlear implants brought in A$1,435.2m, flat in constant currency, even though units rose 5 per cent to 56,692.
  • The Nucleus Nexa System made up more than 95 per cent of developed-market implant sales by June, with an average price increase of about 3 per cent across the portfolio.
  • Cash flow was healthier than earnings.

A new implant platform is reshaping Cochlear’s Business just as its Earnings face a difficult reset. Cochlear (ASX:COH) reported FY26 Underlying Profit of A$322.4 million after weaker trading in several markets, leaving the Nucleus Nexa rollout and a modest FY27 recovery at the centre of its next financial test.

From guidance cut to result

The 18 August result therefore landed near the top of a much lower bar. Underlying net profit fell 22 per cent, or 21 per cent in constant currency. Underlying Earnings Per Share were A$4.93, against A$6.33. Sales Revenue was A$2,343.4m, down 1 per cent as reported and up 2 per cent in constant currency, with second-half constant-currency growth of 6 per cent.

Where the revenue comes from

Cochlear implants brought in A$1,435.2m, flat in constant currency, even though units rose 5 per cent to 56,692. Services, covering sound-processor upgrades and support for existing recipients, generated A$634.9m, up 6 per cent in constant currency. Acoustics, which includes bone-conduction devices, contributed A$273.3m, up 1 per cent.

The geographic split was uneven. In constant currency, the United States rose 4 per cent and Asia Pacific 7 per cent. Western Europe fell 8 per cent, which the company linked to surgery backlogs, strikes and share loss in Germany. Emerging markets fell 2 per cent, with declines in the Middle East and China.

Nexa and margins

The Nucleus Nexa System made up more than 95 per cent of developed-market implant sales by June, with an average price increase of about 3 per cent across the portfolio. A quick platform switch shortens the period of supporting two systems, but gross Margin still fell to 71 per cent from 74 per cent.

Research and development spending rose 15 per cent. For FY27 the company expects R&D of about 13 per cent of sales and gross margin of roughly 70 to 71 per cent, so margin recovery is not in near-term guidance.

Underlying versus statutory

Cash flow was healthier than earnings. Operating Cash Flow was A$368.0m, up from A$237.6m, and free cash flow A$263.5m, up from A$122.4m. Net cash fell to A$187.7m from A$275.7m, keeping the buyback inactive because it sat below the roughly A$200m threshold.

The total Dividend was A$3.45, down 20 per cent from A$4.30: an unchanged A$2.15 interim and a A$1.30 final, 85 per cent franked. The Payout Ratio was 70 per cent of underlying profit.

What management expects for FY27

Guidance is for low single-digit constant-currency revenue growth and underlying net profit of A$330m-A$350m. That is a recovery from A$322.4m, but a small one, with a currency headwind: the guidance assumes the Australian dollar at 70 US cents and 61 euro cents, which management said would cut underlying profit by about 10 per cent against FY26 average rates. Tariffs are assumed to stay at current settings.

Risks and what to watch

Implant volumes: second-half growth of 6 per cent needs to hold, particularly in the United States and Western Europe.